- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04325958
Age Differences in the Effects of Cannabis on Simulated Driving (ADCUF)
The Influence of Age on Driving-related Cannabis Effects: Exploring Cannabis Use Frequency and Related Factors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Epidemiological studies have established that the use of cannabis can increase the risk of a motor vehicle collision. A number of variables can influence the effects of cannabis on driving. For example, frequent users of cannabis have been shown to have different cognitive and physiological responses to cannabis as compared to occasional users. In addition, we know that younger drivers are more likely to be involved in motor vehicle collisions after alcohol use as compared to older users. The contribution of age and experience with cannabis on cannabis-mediated effects on driving have yet to be delineated in laboratory studies. The purpose of the present investigation will be to determine whether cannabis has different effects on driving in young, as compared to middle aged, drivers. Half of each age group will be occasional users of cannabis and the other half will be frequent users.
Eligible participants will attend the laboratory for two test sessions; in one session they will smoke a cannabis cigarette and in the other they smoke a placebo cigarette. Participants will drive a driving simulator before and after smoking the cigarette. Blood for measurement of THC and metabolites will also be collected before smoking the cigarette and at a number of times after smoking. Subjective and cognitive tasks will be completed before and after smoking.
It is hoped that the findings of this study will help to inform public perception and policy into the potential effects of cannabis on driving.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Christine Wickens, PhD
- Phone Number: 34711 416 535-8501
- Email: christine.wickens@camh.ca
Study Contact Backup
- Name: Gina Stoduto
- Phone Number: 34499 416 535-8501
- Email: gina.stoduto@camh.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5S 2S1
- Centre for Addiction and Mental Health
-
Contact:
- Christine Wickens, PhD
- Phone Number: 34711 416-535-8501
- Email: christine.wickens@camh.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- 19-25 or 35-45 years of age;
- Use of smoked cannabis at least once in the past 6 months.
- Use of smoked or vaped cannabis primarily for recreational purposes on up to 1 day per week or on at least 6 days per week in the past 3 months;
- Holds a class G or G2 Ontario driver's licence (or equivalent from another jurisdiction) for at least 12 months;
- Willing to abstain from using alcohol for 24 hours and cannabis for 72 hours prior to Practice and Test Sessions;
- Willing to abstain from all other drugs not prescribed for medical purposes for 48 hours prior to Practice and Test Sessions;
- Resides within Toronto (study site) or can reside with friends/family in Toronto after a Test Session; this area may be extended to the Greater Toronto area if recruitment challenges arise;
- Participant willing to use appropriate contraception until their participation in the study is completed;
- Provides written and informed consent.
Exclusion Criteria
- Use of cannabis primarily for therapeutic purposes, or equally for therapeutic and recreational purposes;
- Diagnosis of medical condition that contraindicates use of cannabis determined by self-report as judged by the Principal Investigator and a study physician; this includes a history of hypersensitivity to cannabinoids smoke, respiratory disease and/or severe cardiovascular, cerebrovascular, renal or liver disease, and bleeding disorders. Smoking cannabis is not recommended for individuals with respiratory diseases, and they will be excluded;
- Diagnosis of psychiatric condition that contraindicates use of cannabis determined by self-report or SCID-5;
- Participants of childbearing potential: Pregnancy (point-of-care test) or breastfeeding;
- Meets criteria for current or lifetime alcohol or other substance use disorder (DSM-5), except tobacco use disorder and caffeine use disorder;
- Is a regular user of medications that affect brain function (based on self-report); this includes concomitant therapy with sedative-hypnotics or other psychoactive drugs
- Use of anti-hypertensives;
- First-degree relative diagnosed with schizophrenia or another psychotic disorder.
- Participation in a past driving study at CAMH (to limit practice effects).
- Participation in a clinical study concurrent with their participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Age group 19 to 25
Participants will complete two sessions: one where they drive the simulator before and after smoking a placebo cannabis cigarette (<1% THC), the other where they drive the simulator before and after smoking an active cannabis cigarette (15% ± 5% THC).
|
750mg cigarette of plant material
Other Names:
750mg cigarette of plant material
Other Names:
|
Other: Age group 35 to 45
Participants will complete two sessions: one where they drive the simulator before and after smoking a placebo cannabis cigarette (<1% THC), the other where they drive the simulator before and after smoking an active cannabis cigarette (15% ± 5% THC).
|
750mg cigarette of plant material
Other Names:
750mg cigarette of plant material
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Standard deviation of lateral position
Time Frame: Before cannabis exposure and 30 minutes and 2 hours after cannabis exposure
|
A measure of 'weaving' when driving the simulator (meters)
|
Before cannabis exposure and 30 minutes and 2 hours after cannabis exposure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Verbal Free Recall Task
Time Frame: Before cannabis exposure and 70 minutes after cannabis
|
A measure of the cognitive effects of cannabis (number correct)
|
Before cannabis exposure and 70 minutes after cannabis
|
Grooved Pegboard Test
Time Frame: Before cannabis exposure and 70 minutes after cannabis
|
A measure of the cognitive effects of cannabis (performance speed in milliseconds)
|
Before cannabis exposure and 70 minutes after cannabis
|
Simple and Choice Reaction Time Tasks
Time Frame: Before cannabis exposure and 70 minutes after cannabis
|
A measure of the cognitive effects of cannabis (milliseconds)
|
Before cannabis exposure and 70 minutes after cannabis
|
Vienna Risk-Taking Test
Time Frame: One hour after cannabis exposure
|
A measure of the amount of risk-taking (latency)
|
One hour after cannabis exposure
|
Mean speed
Time Frame: Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
A measure of the average speed while driving the simulator (km/hr)
|
Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
Standard deviation of speed
Time Frame: Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
A measure of the variability in speed while driving the simulator (km/hr)
|
Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
Maximum speed
Time Frame: Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
A measure of the greatest speed obtained while driving the simulator (in km/hr)
|
Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
Following distance
Time Frame: Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
A measure of the distance between the car being driven and the car in front (meters)
|
Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
Braking latency
Time Frame: Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
A measure of the time it takes to move the foot from the gas pedal to the brake when a stop sign is encountered (seconds)
|
Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
Number of collisions
Time Frame: Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
The number of collisions while driving the simulator (total number)
|
Before cannabis exposure and 25 minutes and 2 hours after cannabis exposure
|
Blood concentration of delta-9-tetrahydrocannabinol (THC)
Time Frame: Before cannabis exposure and 25 minutes and 2 hours after cannabis
|
A measure of the psychoactive component of cannabis in blood (ng/ml)
|
Before cannabis exposure and 25 minutes and 2 hours after cannabis
|
Blood concentration of carboxy-tetrahydrocannabinol (THC-COOH)
Time Frame: Before cannabis exposure and 25 minutes and 2 hours after cannabis
|
A measure of the inactive metabolite of cannabis in blood (ng/ml)
|
Before cannabis exposure and 25 minutes and 2 hours after cannabis
|
Blood concentration of 11-hydroxy-tetrahydrocannabinol (11-OH-THC)
Time Frame: Before cannabis exposure and 25 minutes and 2 hours after cannabis
|
A measure of the active metabolite of cannabis in blood (ng/ml)
|
Before cannabis exposure and 25 minutes and 2 hours after cannabis
|
Systolic blood pressure
Time Frame: Before cannabis exposure and 5, 15, 25 minutes and 1, 2, 3, 4 and 5 hours after cannabis
|
A vital sign (mmHg)
|
Before cannabis exposure and 5, 15, 25 minutes and 1, 2, 3, 4 and 5 hours after cannabis
|
Diastolic blood pressure
Time Frame: Before cannabis exposure and 5, 15, 25 minutes and 1, 2, 3, 4 and 5 hours after cannabis
|
A vital sign (mmHg)
|
Before cannabis exposure and 5, 15, 25 minutes and 1, 2, 3, 4 and 5 hours after cannabis
|
Heart rate
Time Frame: Before cannabis exposure and 5, 15, 25 minutes and 1, 2, 3, 4 and 5 hours after cannabis
|
A vital sign (beats/minute)
|
Before cannabis exposure and 5, 15, 25 minutes and 1, 2, 3, 4 and 5 hours after cannabis
|
Visual Analog Scales such as 'I feel this effect', 'I like this drug effect', 'I feel the good effects'
Time Frame: Before cannabis exposure and 5, 15, 25 minutes and 1, 2, 3, 4 and 5 hours after cannabis
|
A measure of the subjective effects of cannabis (on a scale of 0 to 100, where is 100 is the strongest level of agreement)
|
Before cannabis exposure and 5, 15, 25 minutes and 1, 2, 3, 4 and 5 hours after cannabis
|
Trail Making Test
Time Frame: Before cannabis exposure and 70 minutes after cannabis
|
A measure of the cognitive effects of cannabis (performance speed in seconds)
|
Before cannabis exposure and 70 minutes after cannabis
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christine Wickens, PhD, Centre for Addiction and Mental Health
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 048/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis
-
Centre hospitalier de l'Université de Montréal...RecruitingCannabis | Cannabis Dependence | Cannabis Use | Cannabis Smoking | Cannabis Use, UnspecifiedCanada
-
Elias DakwarRecruitingAddiction | Cannabis Dependence | Cannabis Use | Substance Abuse | Cannabis Abuse | Cannabis Use DisorderUnited States
-
University College, LondonMedical Research Council; InvicroCompletedCannabis | Cannabis Dependence | Cannabis Use | CBD | Adolescent Development | THC | Marijuana | Cannabis IntoxicationUnited Kingdom
-
University of WashingtonNational Institute on Drug Abuse (NIDA)CompletedCannabis Dependence | Cannabis Abuse
-
The University of Tennessee, KnoxvilleColorado State UniversityActive, not recruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedCannabis Dependence | Cannabis AbuseFrance
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
University of VermontDartmouth College; Rutgers UniversityCompletedCannabis Use | Tolerance | Cannabis WithdrawalUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
Yale UniversityRobert E. Leet and Clara Guthrie Patterson Trust Mentored Research AwardRecruitingCannabis | Cannabis Use | Cannabis AbuseUnited States
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Nova Scotia Health AuthorityRecruiting
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Biohaven Pharmaceuticals, Inc.Active, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8United States, China
-
University Hospital, BrestEli Lilly and CompanyCompletedPolymyalgia Rheumatic (PMR)France